IDEAYA Biosciences, Inc.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
IDYA$32.03+2.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Plans
During the three months ended September 30, 2026, our Section 16 officers and directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:
| Name and Title · Action · Adoption Date · Termination Date · Trading Arrangement · Total Shares to be Sold · Expiration Date | |||||
|---|---|---|---|---|---|
| Rule 10b5-1* | Non-Rule 10b5‑1** | ||||
| Yujiro S. HataChairman and Chief Executive Officer | Adopt | July 7, 2026 | X | 330,316 | July 2, 2027 |
| * Intended to satisfy the affirmative defense of Rule 10b5-1(c)** Not intended to satisfy the affirmative defense of Rule 10b5-1(c) | |||||
Exhibit Index
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.